Strategic divestiture Ferring recently divested exclusive global rights to Rebyota and exclusive US rights to Clenpiq to RedHill with upfront and royalties, indicating potential for buyers or partners in adjacent markets. Sales teams should explore license or collaboration opportunities around Ferring’s remaining portfolio and manufacturing capabilities.

Oncology leadership Recent leadership changes in U.S. Oncology and ongoing P&L ownership suggest a focus on strengthening core oncology franchises. This presents cross-sell opportunities for companion diagnostics, clinical trial services, or supportive care products aligned with uro-oncology and GI oncology pipelines.

Academic partnerships Active collaboration with Morehouse School of Medicine and EngagedMD to advance culturally responsive fertility care signals openness to educational, digital adoption, and patient engagement solutions. Potential for training platforms, patient education content, and telemedicine enablement partnerships.

Global footprint Headquartered in Switzerland with subsidiaries in over 50 countries and market presence in more than 100 countries; sizable global logistics, manufacturing, and regulatory capabilities suitable for contract manufacturing, API supply, or regional distribution agreements with third parties.

Sustainability and stability Private ownership with substantial revenue range and a large workforce positions Ferring as a stable partner for long-term strategic collaborations in reproductive medicine, GI, and uro-oncology, including long-duration supply contracts, clinical trial manufacturing, and strategic R&D collaborations.